Advanced search
Publication Cover
Cancer Investigation Volume 29, 2011 - Issue 1
Submit an article Journal homepage
132
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE: CLINICAL TRANSLATIONAL THERAPEUTICS

Thrombin Expression in Prostate: A Novel Finding

Manish KohliDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USACorrespondence[email protected]
,
Karin WilliamsDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
,
Jorge L. YaoDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
,
Richard A. DennisDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
,
Jiaoti HuangDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
,
Jay ReederDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
&
William A. RickeDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA and Department of Urology & Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
 show all
Pages 62-67 | Published online: 17 Dec 2010

REFERENCES

  • Zacharski LR, Memoli VA, Morain WD, Schlaeppi JM, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 1995;73(5):793–797.
  • Guttridge DC, Lau A, Tran L, Cunningham DD. Thrombin causes a marked delay in skeletal myogenesis that correlates with the delayed expression of myogenin and p21CIP1/WAF1. J Biol Chem 1997;272(39):24117–24120.
  • Derian CK, Eckardt AJ. Thrombin receptor-dependent prostaglandin E2 synthesis in hamster fibroblasts: synergistic interactions with interleukin-1beta. Exp Cell Res 1997;232(1):1–7.
  • Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2005;66(3):273–282.
  • Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol 2008;16(1):1–6.
  • Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 2005;11(2 Pt 1):584–593.
  • Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 2006;65(1):19–25.
  • Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest 2009;27(4):430–434.
  • Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434(7031):396–400.
  • Xie WZ, Leibl M, Clark MR, Dohrmann P, Kunze T, Gieseler F. Activation of the coagulation system in cancerogenesis and metastasation. Biomed Pharmacother 2005;59(3):70–75.
  • Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2(12):2107–2114.
  • Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285–291.
  • Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343(25):1846–1850.
  • Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22(10):1944–1948.
  • Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123–2129.
  • Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992;18(1):104–116.
  • Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Moritz TE, Rousseau SM, Stump DC. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991;67(5):1377–1383.
  • Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2006;66(3):273–282.
  • Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002;60(5):760–765.
  • Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA, Pienta KJ. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005;96(3):641–652.
  • Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003;97(3 Suppl):739–747.
  • Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2(7):395–402.
  • Yin YJ, Salah Z, Grisaru-Granovsky S, Cohen I, Even-Ram SC, Maoz M, Uziely B, Peretz T, Bar-Shavit R. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 2003;23(6):940–944.
  • Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 2004;279(20):20927–20934.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.